Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept for Discoid Lupus Erythematosus
NCT00797784Phase 2Unknown
- Sponsor
- Florida Academic Dermatology Centers
- Start
- Oct 2008
- Primary completion
- Apr 2011
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etanercept in discoid lupus erythematosus (DLE), sponsored by Florida Academic Dermatology Centers. Primary endpoint: Proportion of patients responding to study treatment using the Cutaneous Lupus Erythematous Disease Area Severity Index at 20 weeks. Status: unknown.
02
Drugs
etanercept
03
Conditions
discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on NCT00797784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00797784.